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Editorial
Dipeptidyl peptidases and related proteins: multifaceted
markers and therapeutic targets
By far the best known member of this family of pep-
tidases is dipeptidyl peptidase 4 (DPP4, DPPIV, EC
3.4.14.5), an enzyme that was discovered more than
four decades ago. It is expressed in a variety of tis-
sues and a soluble form is present in plasma. It was
found to be identical to the cell surface protein CD26.
Complementary research in clinical chemistry, enzy-
mology and immunology initially investigated the
diagnostic and prognostic value of CD26/DPP4 (1). No
prominent diagnostic value emerged (so far) for the
soluble plasma DPP4, although methods for plasma
DPP4 activity measurements are available since the
1980s. On the other hand, cell surface expression of
DPP4 repeatedly is proposed as a marker for differ-
entiated thyroid carcinoma (2). Within the circulating
lymphocyte population, the CD26bright (also called
CD26high) cells belong to the CD45R0q population and
represent a distinct functional subset of T-cells, which
is responsible for the response to recall antigens, allo-
geneic cells and alloantigens. Monitoring CD26bright
lymphocyte levels is a promising tool during clinical
follow-up in defined conditions, such as immune defi-
ciency or in studies of immune responses to infec-
tious agents or new vaccine candidates (3). Apart
from that, CD26bright cells seem to be enriched in the
course of progenitor cell apheresis. High numbers of
CD26bright cells in the autograft predict a shorter
event-free survival. In this clinical situation, a deple-
tion of CD26bright cells from the peripheral blood stem
cell autograft might be considered (4).
In addition to the search towards the ‘marker’ value
of DPP4/CD26, thorough enzymological and structural
characterization of DPP4 during the 1990s allowed the
development of potent inhibitors (5). The evaluation
of inhibitors in several animal models of disease and
the unexpectedly favorable animal safety profile
forced a breakthrough in the development of DPP4
inhibitors as a new class of therapeutics.
The ‘‘3rd International Conference on Dipeptidyl
peptidases (DPP) & Related Proteins’’ was devoted to
the emerging DPP family of proteases focusing on
basic science, clinical issues and future perspectives.
This conference, a follow-up of a series of successful
meetings organized by Prof. Ansorge in Magdeburg
(6) and Prof. Hildebrandt in Berlin (7) was held in Ant-
werp, April 2008 (8). The ‘multifaceted’ aspects of
DPP4 and related proteins are illustrated in this issue
by the contribution of N. Frerker and colleagues on
the integration of DPP4 in complex biological net-
works. In their papers, S. Ansorge and D. Reinhold
show experimental evidence that some small mole-
cular weight DPP4 inhibitors hit other targets and that
this effect might contribute to their efficacy in certain
preclinical pharmacology studies. Drug discovery
efforts during the past two decades indeed resulted
in the development of a vast amount of small mole-
cular weight DPP4 inhibitors of distinct chemical
structures and beneficial in vivo effects. Perhaps the
time has come to look for additional targets of these
compounds (9). The future will tell whether additional
new classes of therapeutics are hidden in the present
compound libraries and datasets. DPP10, a homolog
of DPP enzymes, has been presented as a potential
new target for asthma therapy (10). K. McNicholas
and colleagues, in this issue, review recent data on
the non-enzyme family members including not only
DPP10 but also DPP6.
While a number of papers in this issue and else-
where highlight future directions of DPP related
research, we should also consider the clinical use of
DPP inhibitors today in relation to laboratory medi-
cine practice.
DPP 4 has become a target in the development of
oral antidiabetics as soon as its role in the in vivo
inactivation of the incretins glucagon-like-peptide 1
(GLP-1) and glucose dependent insulinotropic peptide
became clear (11). The incretins are peptide hor-
mones released in the intestine upon food intake.
GLP-1 enhances insulin release in a glucose depend-
ent manner, suppresses glucagon secretion and
hence lowers blood glucose levels. Animal and in
vitro studies also point to b-cell trophic actions of
GLP-1. In humans, this effect has yet to be demon-
strated (12). The in vivo half-life of GLP-1, however, is
very short. The rapid inactivation occurs by N-termi-
nal truncation by DPP4 that cleaves off a dipeptide.
Small molecule DPP4 inhibitors potentiate and pro-
long the effects of endogenous incretins. They are
called ‘incretin enhancers’. Long-acting stable ana-
logs of GLP-1 also called ‘incretin mimetics’ have
been introduced in diabetes treatment since 2005.
Their parenteral administration is a drawback for
application in early type 2 diabetes care. Two orally
active DPP4 inhibitors are currently used in the treat-
ment of type 2 diabetes: sitagliptin (Januvia) and
vildagliptin (Galvus). Many more are in different
phases of clinical research. Incretin enhancement cer-
tainly is the main mechanism of action of the DPP4
inhibitors but other effects may contribute. Based on
the major mechanism of action, one can assume that
DPP4 inhibitors will have the greatest effect when
started early during the course of type 2 diabetes (11).
To date, two systematic reviews and meta-analyses
of the efficacy and safety of DPP4 inhibitors in type 2
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diabetes have been published (13, 14). DPP4 inhibi-
tors showed HbA1c improvements of 0.7% vs. placebo
in both meta-analyses. The available data suggest
that they are slightly less efficient than other hypo-
glycemic agents. However, when combined with
other antidiabetic compounds, both vildagliptin and
sitagliptin lead to an additional lowering of HbA1c.
Combination therapy of a DPP4 inhibitor with metfor-
min (fixed in Eucreas and Janumet/Efficib) or with
a sulfonylurea is used when metformin and/or sulfo-
nylurea alone proves to be insufficient for glycemic
control. HbA1c is the parameter to be followed during
type 2 diabetes treatment with DPP4 inhibitors. There
is currently no evidence for the use of plasma DPP4
activity measurement in this clinical setting. There are
no clinically meaningful interactions of sitagliptin or
vildagliptin with co-administered medications, such
as oral anticoagulants, so far. Especially in the target
population – type 2 diabetes patients – this is highly
desirable.
Meta-analysis confirmed earlier reports on an over-
all low risk profile of DPP4 inhibitors and no major
side effects were mentioned during therapy (13, 14).
The withdrawal rate due to adverse effects was not
significantly higher in the DPP4 inhibitor groups than
in controls. The lack of major hypoglycemic events is
considered as an important advantage for this new
class of oral antidiabetics. Post-marketing, a few seri-
ous hypersensitivity reactions (including anaphylaxis,
angioedema, rash and exfoliative skin conditions)
have been reported upon use of sitagliptin. For vil-
dagliptin, rare cases of generally asymptomatic
hepatic dysfunction have been reported; they were
without clinical sequellae upon drug withdrawal. After
combining data from clinical studies, Richter et al.
found an increased risk of all-cause infections for sita-
gliptin but not for vildagliptin (14). Amori et al. report
a slightly increased risk of infection for vildagliptin
also (13). The clinical significance is not completely
clear at present, nor can one propose a clearly defined
causative mechanism.
Apart from GLP-1, a number of other biologically
active peptides are truncated by DPP4 (1, 15). For
most of them, physiological relevance of DPP4 for
their metabolism still has to be established. The lack
of appropriate methodology to measure intact vs.
truncated (i.e., minus two amino acids) bio-active
peptides in vivo certainly is one of the main reasons
for this incomplete understanding.
In the near future, methods based on combined
immuno-affinity enrichment and mass spectrometri-
cal detection might become available for various
substrates. This will allow to indisputably and quan-
titatively measure differently processed forms of
bioactive peptides. For B-type natriuretic peptide, the
present insights in the in vivo processing are dis-
cussed further in this issue in the paper by M.
Vanderheyden.
Evidence for the physiologically relevant truncation
of another DPP4 substrate, CXCL12 or Stromal cell
Derived Factor 1 a comes from a recent case report
on an improved engraftment of hematopoietic stem
cell transplantation by DPP4 inhibition with sitagliptin
(16).
Albeit not yet at the sensitivity level one would
dream of in the area of clinically relevant bioactive
peptides, the ‘omics’ approach allows researchers
today to obtain a tissue/plasma wide peptide profile
using multidimensional LC-mass spectrometry
methodologies. Two recent independent studies con-
firm earlier hypotheses on the involvement of DPP4
in the metabolism of proline containing proteins and
peptides (17, 18). DPP4 cleaves with a high efficiency
peptides that have a proline on the penultimate
position. Those peptides are formed to an appreciable
amount, because ‘regular’ aminopeptidases cannot
truncate a peptide just before a proline residue. As
collagen is a proline-rich protein, it is not surprising
that in vivo DPP4 inhibition significantly changes the
profile of collagen derived peptides (17). Collagen is
considered to be the proline reservoir of the body.
Sequential actions of metalloproteinases, peptidases
(e.g., DPP4) and prolidase can increase the free
proline concentration. Whether the in vivo inhibition
of individual steps within the proline mobilization
process finally influences the free proline concentra-
tion and proline metabolism in certain clinical condi-
tions remains to be investigated (19).
New analysis platforms, such as SELDI-TOF mass
spectrometry, allow a further exploration of DPP4/
CD26 and the more recently discovered family mem-
bers as biomarkers during disease or response to
treatment. The discovery of DPP4 as a biomarker dur-
ing follow-up of enzyme replacement therapy in
mucopolysaccharidoses nicely illustrates that the
DPPs and related proteins definitely entered the realm
of clinical and laboratory medicine (20).
In conclusion, DPP inhibitors hold great promise in
the treatment of diabetes and beyond. It is, however,
somewhat premature to predict whether the success
track of angiotensin converting enzyme from a diag-
nostic tool to a highly valuable therapeutic target will
be repeated for DPP4.
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